Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2880070 Monotherapy and Combination with Gemcitabine in Advanced Solid Tumors
NCT02632448Phase 2Completed
- Sponsor
- Esperas Pharma Inc.
- Start
- May 2016
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of LY2880070 in solid tumor, colorectal cancer (CRC), triple-negative breast cancer (TNBC) and 4 more (10 arms), sponsored by Esperas Pharma Inc. Primary endpoint: Maximum Tolerated Dose at 21 days. Started May 2016; status: completed.
02
Drugs
LY2880070
03
Conditions
solid tumorcolorectal cancer (CRC)triple-negative breast cancer (TNBC)ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT02632448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632448.